Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 5/20 | 0.61 |
| ▸ | PPARG | P37231 | 4/20 | 0.61 |
| ▸ | FBP1 | P09467 | 9/20 | 0.57 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31357666 | 1.00 | PPARA (0.61) | PPARAPPARGFBP1ABCB11CYP1A2 | |
| SCHEMBL20730087 | 0.85 | PPARA (0.64) | PPARAPPARGFBP1ABCB11CYP1A2 | |
| SCHEMBL197882 | 0.85 | PPARA (0.64) | PPARAPPARGFBP1ABCB11CYP1A2 | |
| SCHEMBL23134009 | 0.85 | PPARA (0.45) | PPARAPPARGFBP1ABCB11CYP1A2 | |
| SCHEMBL12670824 | 0.84 | PPARA (0.62) | PPARAPPARGFBP1ABCB11CYP1A2 | |
| SCHEMBL2916587 | 0.83 | CYP1A2 (0.49) | PPARAPPARGFBP1CYP1A2CYP3A4 | |
| SCHEMBL6091395 | 0.83 | PPARA (0.69) | PPARAPPARGFBP1ABCB11CYP1A2 | |
| SCHEMBL7988059 | 0.82 | PPARA (0.61) | PPARAPPARGFBP1ABCB11CYP1A2 | |
| SCHEMBL4422408 | 0.82 | PPARA (0.68) | PPARAPPARGFBP1ABCB11CYP1A2 | |
| SCHEMBL655568 | 0.82 | PPARA (0.61) | PPARAPPARGFBP1ABCB11CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630528-B2 | Amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof | LG CHEM, LTD. (KR) | 2026-05-19 | — | — | US | disclosed |
| EP-4071147-B1 | NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF | LG CHEMICAL LTD (KR) | 2025-03-26 | — | — | EP | disclosed |
| US-20230078941-A1 | NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF | LG CHEM, LTD. (KR) | 2023-03-16 | — | — | US | disclosed |
| WO-2023280177-A1 | SMALL MOLECULE COMPOUND TARGETING BCL9/β-CATENIN INTERACTION | 南通聚太生物科技有限公司 | 2023-01-12 | — | — | WO | disclosed |
| US-20220363667-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-11-17 | — | — | US | disclosed |
| EP-4071147-A1 | NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF | Lg Chem, Ltd. (KR) | 2022-10-12 | — | — | EP | disclosed |
| CN-114846013-A | Novel aminoaryl derivatives useful as diacylglycerol acyltransferase 2 inhibitors and uses thereof | 株式会社LG化学 | 2022-08-02 | — | — | CN | disclosed |
| US-20220226299-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-07-21 | — | — | US | disclosed |
| EP-3950059-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | Nippon Chemiphar Co., Ltd. (JP) | 2022-02-09 | — | — | EP | disclosed |
| US-20210206758-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-07-08 | — | — | US | disclosed |
| US-7713971-B2 | 1,2,4-triazine derivatives, preparation and use thereof in human therapy | PIERRE FABRE MEDICAMENT (FR) | 2010-05-11 | — | — | US | disclosed |
| US-7713971-B2 | 1,2,4-triazine derivatives, preparation and use thereof in human therapy | PIERRE FABRE MEDICAMENT (FR) | 2010-05-11 | — | — | US | disclosed |
| US-20100004159-A1 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES | GENFIT (FR) | 2010-01-07 | — | — | US | disclosed |
| US-20100004159-A1 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES | GENFIT (FR) | 2010-01-07 | — | — | US | disclosed |
| US-20100004159-A1 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES | GENFIT (FR) | 2010-01-07 | — | — | US | disclosed |
| EP-1856065-B1 | 1,2,4-TRIAZINE DERIVATIVES, PREPARATION AND USE THEREOF IN HUMAN THERAPY | PF MEDICAMENT (FR) | 2009-11-11 | — | — | EP | disclosed |
| US-20080167313-A1 | 1,2,4-Triazine Derivatives, Preparation and Use Thereof in Human Therapy | PIERRE FABRE MEDICAMENT (FR) | 2008-07-10 | — | — | US | disclosed |
| US-20080167313-A1 | 1,2,4-Triazine Derivatives, Preparation and Use Thereof in Human Therapy | PIERRE FABRE MEDICAMENT (FR) | 2008-07-10 | — | — | US | disclosed |
| US-20080167313-A1 | 1,2,4-Triazine Derivatives, Preparation and Use Thereof in Human Therapy | PIERRE FABRE MEDICAMENT (FR) | 2008-07-10 | — | — | US | disclosed |
| WO-2005080354-A1 | 1,2,4-TRIAZINES DERIVATIVES, PREPARATION THEREOF AND USE THEREOF IN HUMAN THERAPEUTICS | PIERRE FABRE MEDICAMENT (FR) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206758-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | ITGB6, ITGA6, ITGB3 | PPARA 2435/4885PPARG 2447/4885FBP1 3876/4885 |
| US-20100004159-A1 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES | IPO5, PPIP5K2, IPO4 | PPARA 1045/4885PPARG 422/4885FBP1 2382/4885 |
| US-20080167313-A1 | 1,2,4-Triazine Derivatives, Preparation and Use Thereof in Human Therapy | CBR3, NOX3, RTN3 | PPARA 3384/4885PPARG 2530/4885FBP1 3682/4885 |
| US-20230078941-A1 | NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF | DGAT2, DGAT1, PLAAT2 | PPARA 295/4885PPARG 170/4885FBP1 1929/4885 |
| US-12630528-B2 | Amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof | DGAT2, DGAT1, SOAT2 | PPARA 421/4885PPARG 212/4885FBP1 2106/4885 |
| US-20220363667-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | CACNA1I, CACNA1G, CACNA1H | PPARA 3839/4885PPARG 4069/4885FBP1 3565/4885 |
| US-20220226299-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | TRPV3, CACNA1G, TRPV2 | PPARA 3704/4885PPARG 4254/4885FBP1 4120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.